Replies to post #42446 on Biotech Values

[DewDiligence]

>Throw out ANA380 - what value does that give ANDS?<

That depends greatly on whether they can get ANA975 back into the clinic. Without ANA975, the situation would be bleak, IMO.

After the CEO’s sudden departure last year—timed perfectly to preempt the announcement that ANA975 was on clinical hold—ANDS is not likely to get the benefit of the doubt from the investment community.

>Do you - or does anyone - have any feel for their antibacterial program?<

Sorry, I don’t.